Hereditary nonpolyposis colorectal cancer (HNPCC)
|
|
- Denis Harrington
- 6 years ago
- Views:
Transcription
1 GASTROENTEROLOGY 2000;118: Controlled 15-Year Trial on Screening for Colorectal Cancer in Families With Hereditary Nonpolyposis Colorectal Cancer HEIKKI J. JÄRVINEN,* MARKKU AARNIO,* HARRI MUSTONEN,* KATJA AKTAN COLLAN, LAURI A. AALTONEN, PÄIVI PELTOMÄKI, ALBERT DE LA CHAPELLE, and JUKKA PEKKA MECKLIN *Second Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland; Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland; Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; and Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland See editorial on page 969. Background & Aims: Identification of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome enables prevention of colorectal cancer (CRC) by means of colonoscopy and polypectomies. We evaluated the efficacy of screening in a controlled trial over 15 years. Methods: Incidence of CRC and survival were compared in 2 cohorts of at-risk members of 22 families with HNPCC. Colonic screening at 3-year intervals was arranged for 133 subjects; 119 control subjects had no screening. Genetic testing was offered to subjects in whose families the causative mutation was known. Results: CRC developed in 8 screened subjects (6%) compared with 19 control subjects (16 %; P 0.014). The CRC rate was reduced by 62%. In mutationpositive subjects alone, the CRC rates were 18% in screened subjects and 41% in controls (P 0.02). The decrease resulted from the removal of adenomas in 13 mutation-positive individuals (30%) and in 6 subjects with unknown mutation status (40%). All CRCs in the study group were local, causing no deaths, compared with 9 deaths caused by CRC in the controls. The overall death rates were 10 vs. 26 subjects in the study and control groups (P 0.003), 4 vs. 12 in mutationpositive subjects (P 0.05). Conclusions: Colonoscopic screening at 3-year intervals more than halves the risk of CRC, prevents CRC deaths, and decreases overall mortality by about 65% in HNPCC families. Hereditary nonpolyposis colorectal cancer (HNPCC) is a mendelian-dominant cancer syndrome characterized by a high risk of colorectal cancer (CRC) and endometrial cancer at a young age, 1 and an increased risk of many less frequent tumor types, such as gastric, ovarian, renal cell, uroepithelial, and biliary tract adenocarcinomas. 2 Mutations in 1 of 5 DNA mismatch repair genes cause the cancer susceptibility. 3 6 Identification of a specific germline mutation in a member of a clinically suspected family enables predictive genetic testing to be offered to at-risk family members. Public and professional awareness of the existence and nature of HNPCC and the high risk of CRC (greater than 80% 2,7 ) associated with its germline mutations have led to the detection of increasing numbers of cancer-free individuals who are mutation positive. It is therefore very important to devise strategies to prevent cancer or cancer death in such individuals through clinical screening. Colonoscopy is one potential tool for the detection and treatment of premalignant adenomas or early CRC probably resulting in improved survival. 8,9 We previously reported on a cohort of at-risk members of HNPCC families that were offered colonoscopic screening beginning in After 10 years of study, a statistically significant reduction in CRC rate was noted as a result of polypectomies in individuals who opted for screening compared with those who did not. 10 We now describe the results after completion of 15 years of this study. Importantly, we have now conducted predictive mutation analyses in the majority of the entire cohort and are able to correlate clinical data in screened subjects and controls with their mutation status. Materials and Methods Subjects and Examinations The subjects consisted of 252 asymptomatic individuals, aged years, belonging to 22 HNPCC families and being at 50% a priori risk to be mutation carriers. The inclusion criteria, selection of subjects to the study and control groups by free choice, and screening procedures have been described in detail previously. 10 The final study group of 133 subjects had their first colonic examination between 1982 and 1986, whereas the 119 control subjects declined screening (78 Abbreviations used in this paper: CI, confidence interval; CRC, colorectal cancer; HNPCC, hereditary nonpolyposis colorectal cancer by the American Gastroenterological Association /00/$10.00 doi: /gg
2 830 JÄRVINEN ET AL. GASTROENTEROLOGY Vol. 118, No. 5 subjects) or could not be traced (41 subjects), and were not contacted before genetic testing became feasible in The 78 subjects declining screening were personally contacted and informed about the increased cancer risk in their family at least once, often several times. One previously unknown at-risk family member was added to the control group. The original study plan was approved by the ethical committee of the Medical Faculty of Helsinki University and Helsinki University Hospital. The study and control groups were comparable in terms of mean ( SD) age ( vs years at the beginning of study) and sex (73 men and 60 women vs. 59 men and 60 women). At the end of 1998, the median follow-up time was 14.5 years (range, 2 years 8 months to 16 years) in the study group and 15 years (range, 1 year 4 months to 15 years) in the control group. The number of person-years at the follow-up was 1854 in the study group and 1618 in controls. The point of reference for the start of the study was the date of the first examination in the study group and January 1, 1984, in the control group. A mutated MLH1 gene has been shown to segregate in 19 of the families. Finnish founder mutation 1 (deletion of exon 16) occurs in 13 families; founder mutation 2 (a splice site mutation leading to the loss of exon 6) occurs in 2 families. Three different mutations in exons 3 5, 12, and 17 account for 1 family each One family has a mutation in the MSH2 gene (exon 12), and a suspected DNA mismatch repair gene mutation that has not yet been fully characterized occurs in another family. In 2 families, no germline mutations have yet been identified; one of these fulfills the clinical diagnostic criteria for HNPCC (Amsterdam criteria), 14 the other does not. Predictive genetic testing for the mutation segregating in each particular family was offered for 205 individuals and performed in 193 study subjects between 1996 and 1998: 116 in the study group and 77 in the controls. Before testing, the subjects were counseled individually and gave written, informed consent. Three subjects (who died of cancer) were classified as obligate mutation-positive carriers because at least 1 child had the expected mutation. Six further subjects were regarded as mutation positive because they had a cancer belonging to the HNPCC tumor spectrum: CRC (2), renal cell adenocarcinoma (2), endometrial cancer (1), and lymphoma (1). In total, there were 44 mutation-positive and 74 mutationnegative individuals in the study group compared with 46 positive and 38 negative in the controls. Mutation status was unknown in 50 subjects (15 study subjects and 35 controls): 17 had died before testing was available, 12 declined testing (2 were study subjects and 10 controls), and the remaining 21 subjects belonged to families with no test available. After initial colonoscopy (43 subjects) or double-contrast barium enema and sigmoidoscopy (90 subjects), the examination was repeated at 3-year intervals, and the use of colonoscopy has reached nearly 100%. Actually, the original screening interval was 5 years. An approximately 5-year interval between the first and second examination did occur in 40% of the subjects. The 3-year interval was followed since Polyps detected were removed by snare polypectomy when appropriate. Four subjects underwent total abdominal colectomy (3 in the study group, 1 in the control group) and 1 subject (study group) a segmental resection of the sigmoid colon either for large adenomas, severe dysplasia (2 subjects), or simply to facilitate further surveillance. CRC was treated by means of total abdominal colectomy in all study group subjects and in 9 control group cases; 10 control patients underwent hemicolectomy or segmental resection. Of the latter, 7 had palliative surgery for disseminated CRC, whereas in 2 cases the HNPCC background was not recognized at the time of surgery and 1 patient had anterior resection for rectal cancer. The planned screening program was considered complete or nearly complete with some delays in 123 study subjects (93%). Of the 10 noncompliant subjects, 5 have died of causes other than CRC (1 mutation positive) and 4 have had negative gene test results. The control subjects were not actively contacted after 1986, but screening was arranged when requested. This happened in 24 control subjects (20%) between 1988 and After genetic testing, all mutation-positive subjects were recommended screening, whereas endoscopies were discontinued in mutation-negative subjects in whom no adenomas had been found. At present, excluding mutation-negative subjects (38) and those who have died (27), most of the control subjects are participating in screening (34/54). Data Collection and Statistical Analysis The cancer morbidity data, survival, and causes of death in each group were checked at the Finnish Cancer Registry and the Population Registry of Finland considering December 31, 1998, as the closing date. For persons living abroad, foreign consulates and national registries in Sweden and Norway were contacted in addition to questioning of relatives. Clinical data including tumor site and stage, classified according to the modified Dukes system, 15 were obtained from the hospital records. All analyses between the study and control groups were performed with an intent-to-treat principle disregarding any dropouts from screening in the study group or examinations outside the original study plan in the controls. Differences between 2 proportions were tested using the Fisher exact test (2-tailed) or the Mann Whitney U test. Cumulative incidences of CRC and survival rates were calculated using the Kaplan Meier product limit method, and the significance of differences was tested by the log rank test. The significance of a trend in proportions falling into a natural order was tested with exact Cochran Armitage trend test. Results The number of subjects developing CRC was 8 (6%) of 133 in the study group compared with 19 (16%) of 119 in the control group (P 0.014). The relative risk
3 May 2000 SCREENING FOR COLORECTAL CANCER IN HNPCC 831 of CRC was (95% confidence interval [CI], ) in the study group vs. controls, corresponding to a reduction of 62% (95% CI, 17% 83%). Considering only known mutation-positive subjects, the frequencies of CRC were 18% (8 of 44) in the study group and 41% (19 of 46) in the controls (P 0.02). The corresponding relative CRC risk of the screened mutationpositive individuals was (95% CI, ) and the reduction due to screening 56% (95% CI, 10% 79%). The cumulative proportions of CRC-free subjects were significantly higher in the study group than control group both when all subjects (P 0.019) and when mutation-positive subjects alone (P 0.034) were included (Figure 1). Also, the stage distribution of the CRCs in the study subjects was significantly more favorable than that in the control group (Table 1). Two CRCs in the screening group were detected at the first examination (stages A and B). The remaining 6 CRC patients, 2 with stage A and 4 with stage B tumors, had undergone previous colonoscopies with no findings 26, 34, 36, 37, 59, and 60 months before the diagnostic screening examination. Two of the 19 CRC cases in the control group were detected in a screening colonoscopy, 1 outside the study plan (stage A) and the other after a positive genetic test result (2 tumors, both stage B). Adenomas were detected exclusively in screening examinations, in 31 study subjects (23%) and in 4 controls (3%; P 0.001). Two of the latter were detected after the genetic testing had shown a mutation. Adenomas were detected in 15 mutation-positive individuals and in 8 subjects whose mutation status was unknown, but also in 12 mutation-negative subjects. The adenomas were larger in mutation-positive subjects (mean, 6.7 mm; range, 1 20 mm) than in mutation-negative subjects (mean, 3.1 Table 1. Stage Distribution of CRC Cases Stage a Study group (n 133) Control group (n 119) A 3 3 B 5 7 C 1 D 8 Total 8 19 a The stages in the study group were significantly more favorable than in the control group (P 0.03). mm; range, 1 10 mm; P 0.02), and the age was younger at the time of adenoma detection (mutationpositive: mean, 42.2 [range, 24 65] years vs. mutationnegative: 48.5 [range, 36 78] years; P 0.16). Severe dysplasia was found in 2 of 25 adenomas in mutationpositive subjects compared with none of 19 adenomas in mutation-negative subjects. Among all the subjects who had at least 1 complete colonoscopy, the 85 mutationpositive subjects had a 3.4-fold frequency of colorectal neoplasms compared with 83 negatives, 44 (52%) vs. 12 (14%; P 0.001). The sites of the neoplastic lesions were characteristically more proximal in mutation-positive than mutation-negative subjects (Figure 2). No significant complications were observed after more than 600 screening colonoscopies/sigmoidoscopies. None of the 133 subjects in the study group has died of CRC compared with 9 of 119 (8%) among the control subjects (P 0.001). The overall 5-year survival rate of the present CRC patients was 67%: 100% in the study group and 54% in the control group. Altogether, there were 10 deaths (8%) in the study group compared with 26 deaths (22%) in controls within the 15-year period (P 0.001; Table 2). Four (9%) and 12 (26%) of the deaths occurred in known mutation-positive subjects (P 0.05). The relative risks of death for the screened subjects vs. controls within the study period were (95% CI, ) and (95% CI, Figure 1. Cumulative proportion of subjects free of CRC. a P between the screening and control groups including all subjects. b P between mutation-positive subjects of the screening and control groups. Figure 2. Locations of all neoplastic tumors detected within 15 years: (A) mutation-positive subjects (n 85); (B) mutation-negative subjects (n 83)., CRC; a, metachronous CRC;, adenoma.
4 832 JÄRVINEN ET AL. GASTROENTEROLOGY Vol. 118, No. 5 Table 2. Causes of Death Within the 15-Year Study Period Cause Study group (n 133) Control group (n 119) CRC a 9 Gastric cancer a 1 Bile duct carcinoma a 1 Lymphoma a 1 1 Glioblastoma multiforme a 1 Renal cell carcinoma a 1 Pulmonary embolism (postoperative) a 1 Heart attack 4 3 Cerebral hemorrhage 1 2 Duodenal ulcer hemorrhage 1 Pulmonary disease 3 Suicide 1 1 AIDS 1 Accident/violence 3 Total AIDS, acquired immunodeficiency syndrome. a Cause related to the HNPCC syndrome ) for all subjects and for mutation-positive subjects, respectively. Thus, the corresponding reductions in death rate were 66% (95% CI, 32% 83%) or 65% (95% CI, 0.1% 88%). Other HNPCC-related cancers occurred in 23 study subjects (Table 3), and were responsible for all 4 deaths of mutation-positive subjects in the study group and 2 deaths in the control group. One control subject died of pulmonary embolism after a successful colectomy for a severely dysplastic adenoma detected in screening colonoscopy after a positive gene test result. The cumulative overall survival was significantly better in the original study group than control group (P 0.003) and also significant (P 0.05) if mutation-positive subjects only were compared (Figure 3). Of note, an additional Table 3. Extracolonic Cancers and Tumors Within the 15-Year Study Period Tumor type/site Study group (n 133) Control group a (n 119) Endometrial cancer 5 5 Ovarian cancer 3 c Gastric cancer 2D b 1 Urinary bladder/ureteric cancer 2 Lymphoma 1D 1D Renal cell adenocarcinoma 2D Cholangiocarcinoma 1D Epidermoid carcinoma (skin) 1 Melanoma 1 Brain (glioblastoma multiforme) 1D Acoustic neurinoma 1 b Breast 1 b Total 14 (12 patients) 14 (11 patients) D, each D denotes a case of death. a An additional subject had a meningioma within the study period; he tested negative for mutation. b One metachronous tumor. c Two metachronous tumors. Figure 3. Cumulative overall survival. a P between the screening and control groups including all subjects. b P 0.05 between mutation-positive subjects of the screening and control groups. subject in the control group died of CRC less than 2 months after the closing date of the study. Discussion The most important new finding of our extended screening trial was that colonoscopic screening and polypectomies not only reduce the incidence of CRC but also decrease the overall death rate by approximately 65%. This reduction was largely a result of the complete prevention of CRC deaths in the screened subjects compared with 9 deaths among 19 CRC cases in control subjects. The survival advantage was statistically significant both between the original study groups and in the subgroups composed exclusively of mutation-positive subjects. The difference in survival rate was marginal (P 0.05) in mutation-positive individuals. Because all subjects of the 2 groups could not be tested but the mutation status was deduced as positive in 6 cases (2 study subjects, 4 controls) by typical tumor status (e.g., lymphoma), the significance of the survival difference may be questioned if one or more of these tumors (in controls) were in fact unrelated to HNPCC. However, several arguments can be adduced to support the view that a real difference in favor of screening indeed exists. First, an increasing number of control subjects underwent screening examinations during the latter period of the trial, resulting in the detection and treatment of asymptomatic adenomas, and even 2 early-stage CRC cases, thus weakening the power of the study. Second, an additional case of death due to CRC was observed in the control group immediately after the closing date of the study, illustrating the fact that CRC deaths continue to
5 May 2000 SCREENING FOR COLORECTAL CANCER IN HNPCC 833 occur in these individuals not surveilled. On the other hand, ascertainment bias cannot be totally excluded because the selection between the 2 groups was not random. For example, socioeconomic status may have influenced the acceptance of screening, and nonacceptance may be associated with excess of morbidity due to poor health awareness. However, formal randomization of members of the same family to screening or no screening was considered impossible at the beginning of the study. With the possibility for genetic tests, such a randomization is even more problematic now. In survival, the screening group benefited from complete prevention of CRC deaths, yet suffered from the common occurrence of extracolonic cancers. These caused (probably by chance) more deaths in the study group than control group, 4 vs. 2 cases, respectively. In total, 28 tumors of 12 different types were diagnosed in 23 subjects. The frequencies of subjects with extracolonic tumors were 12 (27%) and 11 (24%) in the mutationpositive subjects of the study and control groups, respectively. Because the CRC rates were 18% and 41% in the same groups, it is clear that detecting extracolonic cancer becomes increasingly critical when the CRC risk is largely controlled under colonoscopic surveillance. Interestingly, in female mutation-positive subjects, the risk of endometrial cancer exceeds that of CRC even before any screening arrangements. 2,16 The appropriate screening methods and intervals remain to be solved in future studies, but this is not easy in view of the multiple predisposed organ sites and the relative rarity of most of the cancer types involved. 2 We have started offering screening for endometrial cancer using vacuum abrasion in mutation-positive women. In this particular series the outcome for most subjects with extracolonic cancer was favorable, and it is difficult to see how cases with a fatal outcome could have been managed better. The most cost-effective interval of screening colonoscopies also remains open for future trials. Many authorities suggest that the interval should be shorter than the 3 years used in the present trial, perhaps only 1 or 2 years. 17,18 The efficacy in the prevention of deaths could not have been improved in our trial, but some CRC cases might have been prevented at an adenoma stage and treated without surgery if shorter intervals had been used. Actually, the figures for the reduction in the CRC rate by 62% overall, or 56% in mutation-positive subjects, are underestimates because 2 CRC cases detected during the first screening visit were included and in 2 other cases the screening intervals were 59 and 60 months instead of the planned 36 months. 9 The problem of overlooked adenomas remains despite more frequent endoscopies, and this hazard cumulates with time. Therefore, the option of prophylactic colectomy must be borne in mind as one alternative to repeated colonoscopies. 19 However, prophylactic surgery carries an additional risk of complications, or even death, as observed in 1 control patient who died of pulmonary embolism. The number of subjects who had adenomas removed during the 15-year screening was quite low among the mutation-positive individuals (30%). In fact, mutationnegative subjects had almost as many adenomas, although the total number of neoplasms in the colon was much higher in mutation-positive subjects. Additionally, the age at detection of adenomas was slightly younger in mutation-positive than -negative subjects. It can be seen that an equal number of CRCs would have developed in the 2 groups if the adenomas of 11 mutation-positive subjects had not been removed during screening but progressed to cancer. Our observations support the view that the adenoma-carcinoma sequence is accelerated and almost guaranteed in HNPCC. 20,21 In conclusion, this long-term screening trial proved that repeated colonoscopies can reduce the CRC rate in at-risk or mutation-positive members of HNPCC families by at least 56% 62%, prevent CRC deaths, and reduce overall mortality by about 65%. Given that CRC will largely be controlled by colonoscopic surveillance, the increasing problem of the occurrence of extracolonic cancers at several organ sites merits further attention in screening programs. References 1. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996;78: Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin J-P, Järvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81: Rhyu MS. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. J Natl Cancer Inst 1996;88: Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yanuso M, Igari T, Koikechiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17: Kinzler KW, Vogelstein B. Lessons from the hereditary colorectal cancer. Cell 1996;87: Peltomäki P, Vasen HFA. The ICG on HNPCC. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 1997;113: Vasen HFA, Wijnen J Th, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard M-L, Mohr J, Fodde R, Meera Khan P. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110: Vasen HFA, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, Offenhaus GJA, Meera Khan P. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995;31A:
6 834 JÄRVINEN ET AL. GASTROENTEROLOGY Vol. 118, No Vasen HFA, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM, Menko FH, Meera Khan P. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82: Järvinen HJ, Sistonen P, Mecklin J-P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108: Nyström-Lahti M, Kristo P, Nicolaides NC, Chang S-Y, Aaltonen LA, Moisio A-L, Järvinen HJ, Mecklin J-P, Kinzler KW, Vogelstein B, de la Chapelle A, Peltomäki P. Founding mutations and Alu-mediated recombination in hereditary cancer. Nat Med 1995;1: Nyström-Lahti M, Wu Y, Moisio A-L, Hofstra RMW, Osinga J, Mecklin J-P, Järvinen HJ, Leisti J, Charles HC, Buys M, de la Chapelle A, Peltomäki P. DNA mismatch gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996;5: Holmberg M, Kristo P, Chadwicks RB, Mecklin J-P, Järvinen HJ, de la Chapelle A, Nyström-Lahti M, Peltomäki P. Mutation sharing, predominant involvement of the MLH1 gene and description of four novel mutations in hereditary non-polyposis colorectal cancer. Hum Mutat 1998;11:482 [Mutation Note 144; online 1997]. 14. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991;34: Davis NC, Evans EB, Cohen JR, Theile DE. Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes system. Dis Colon Rectum 1984;26: Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA-mismatch-repair gene mutation. Hum Mol Genet 1997;6: Vasen HFA, Nagengast FM, Meera Khan P. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995;345: Thorson AG, Knezetic JA, Lynch HT. A century of progress in hereditary nonpolyposis colorectal cancer (Lynch syndrome). Dis Colon Rectum 1999;42: Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996;28: Ahlquist DA. Aggressive polyps in hereditary nonpolyposis colorectal cancer: targets for screening. Gastroenterology 1995;108: Jass JR, Stewart SM, Lane MR. Hereditary non-polyposis colorectal cancer morphologies, genes and mutations. Mutat Res 1994;310: Received July 27, Accepted January 13, Address requests for reprints to: Heikki J. Järvinen, M.D., Second Department of Surgery, Helsinki University Central Hospital, P.O. Box 260, FIN HUCH, Helsinki, Finland. Fax: (358) Supported by grants from the National Institutes of Health (CA and CA 16058), European Union (BMH4-CT ), Foundation for Gastroenterological Research in Finland, the Sigrid Juselius Foundation, and the Finnish Cancer Foundation. The authors thank Dr. Annika Lindblom for the genetic testing of several subjects living in Sweden and Tuula Lehtinen, Kirsi Pylvänäinen, and Marjo Molin for organizing the screening, genetic testing, and data collection.
Review Article Clinicopathological Features and Management of Cancers in Lynch Syndrome
Pathology Research International Volume 2012, Article ID 350309, 6 pages doi:10.1155/2012/350309 Review Article Clinicopathological Features and Management of Cancers in Lynch Syndrome Markku Aarnio Department
More informationT he lifetime risk of developing colorectal cancer is 5%, with. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer CANCER
228 CANCER Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer G Lindgren, A Liljegren, E Jaramillo, C Rubio, A Lindblom... See end of article for authors affiliations... Correspondence
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 338 M AY 21, 1998 NUMBER 21 INCIDENCE OF HEREDITARY NONPOLYPOSIS COLORECTAL CANCER AND THE FEASIBILITY OF
More informationRisk of colorectal and endometrial cancer for carriers of mutations of the hmlh1 and hmsh2 gene: correction for ascertainment
491 SHORT REPORT Risk of colorectal and endometrial cancer for carriers of mutations of the hmlh1 and hmsh2 gene: correction for ascertainment F Quehenberger, H F A Vasen, H C van Houwelingen... Background:
More informationFamilial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a nationwide epidemiological study from Sweden
doi: 10.1054/ bjoc.2001.1718, available online at http://www.idealibrary.com on http://www.bjcancer.com Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a nationwide epidemiological
More informationA positive family history has been shown to be an important
335 LETTER TO JMG Hereditary non-polyposis colorectal cancer: current s of colorectal cancer largely overestimated J Carayol, M Khlat, J Maccario, C Bonaïti-Pellié... A positive family history has been
More informationORIGINAL INVESTIGATION. Colon Cancer Screening Practices Following Genetic Testing for Hereditary Nonpolyposis Colon Cancer (HNPCC) Mutations
ORIGINAL INVESTIGATION Colon Cancer Screening Practices Following Genetic Testing for Hereditary Nonpolyposis Colon Cancer (HNPCC) Mutations Chanita Hughes Halbert, PhD; Henry Lynch, MD; Jane Lynch, BSN;
More informationExtensive Surgery in LS factoring in gene and gender. Gabriela Möslein
Extensive Surgery in LS factoring in gene and gender Gabriela Möslein Where we are coming from. Non polyposis colon cancer Recommend subtotal colectomy at the time of the first colon cancer Recommend prophylactic
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationMr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
More informationCancer Risk in Families With Hereditary Nonpolyposis Colorectal Cancer Diagnosed by Mutation Analysis
GASTROENTEROLOGY 1996;110:1020 1027 Cancer Risk in Families With Hereditary Nonpolyposis Colorectal Cancer Diagnosed by Mutation Analysis HANS F. A. VASEN,*,, JUUL Th. WIJNEN, FRED H. MENKO, Ø JAN H. KLEIBEUKER,
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationPredictive Genetic Testing and Counselling for Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
Department of Medical Genetics, The Family Federation of Finland and Department of Medical Genetics, Haartman Institute University of Helsinki Predictive Genetic Testing and Counselling for Hereditary
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationMSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table
MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationQuality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?
Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.
More informationCLINICAL FINDINGS WITH IMPLICATIONS FOR GENETIC TESTING IN FAMILIES WITH CLUSTERING OF COLORECTAL CANCER
CLINICAL FINDINGS WITH IMPLICATIONS FOR GENETIC TESTING IN FAMILIES WITH CLUSTERING OF COLORECTAL CANCER CLINICAL FINDINGS WITH IMPLICATIONS FOR GENETIC TESTING IN FAMILIES WITH CLUSTERING OF COLORECTAL
More informationCascade genetic testing for mismatch repair gene mutations
Familial Cancer (2008) 7:293 301 DOI 10.1007/s10689-008-9192-x Cascade genetic testing for mismatch repair gene mutations R. J. Mitchell Æ R. K. Ferguson Æ A. Macdonald Æ M. G. Dunlop Æ H. Campbell Æ M.
More informationMLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table
MLH1 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Cancer (HNPCC) MLH1 Summary Cancer Risk Table CANCER GENETIC CANCER RISK Endometrial Other MLH1 gene Overview Lynch syndrome 1,
More informationNuclear Pedigree Criteria of Suspected HNPCC
pp. 34-38 Nuclear Pedigree Criteria of Suspected HNPCC Józef K³adny 1, Gabriela Möslein 2, Torben Myrhøj 3, Grzegorz Kurzawski 4, Anna Jakubowska 4, Tadeusz Dêbniak 4, Wojciech Petriczko 1, Micha³ Koz³owski
More informationPMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table
PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationORIGINAL INVESTIGATION. Association Between Colorectal Cancer and Urologic Cancers
ORIGINAL INVESTIGATION Association Between Colorectal and Urologic s Audrey H. Calderwood, MD; Dezheng Huo, hd; David T. Rubin, MD Background: Different types of urologic cancers have been associated with
More informationFACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?
Important points The most important factors that can influence an individual s chance of developing bowel cancer are getting older and having a family history of bowel cancer A family history of bowel
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationChapter 9 Hereditary Nonpolyposis Colorectal Cancer
Chapter 9 Hereditary Nonpolyposis Colorectal Cancer W. Donald Buie and Anthony R. MacLean Hereditary nonpolyposis colorectal cancer (HNPCC) is one of two distinct inherited colorectal cancer syndromes
More information2018 National Academy of Medicine Annual Meeting
2018 National Academy of Medicine Annual Meeting October 15, 2018 Targeting Cancer with Precision Prevention Ernest Hawk, M.D., M.P.H. What is Precision Prevention? The concept of precision medicine prevention
More informationIncidence and Clinical Characteristics of Colonic and Extra Colonic Lynch Syndrome Manifestations in Uruguayan Mismatch Repair Carriers
Research Article imedpub Journals http://www.imedpub.com/ Colorectal Cancer: Open Access ISSN 47-9943 07 Vol.3 No.:6 DOI: 0.767/47-9943.00036 Incidence and Clinical Characteristics of Colonic and Extra
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationLynch Syndrome. A Patient s Guide to Genetic Testing for Lynch Syndrome
Lynch Syndrome A Patient s Guide to Genetic Testing for Lynch Syndrome What is Lynch Syndrome? Lynch syndrome is an inherited condition that increases your risk of developing colon cancer and other cancers
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationClinicopathological Features and Type of Surgery for Lynch Syndrome: Changes during the Past Two Decades
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(2):605-611 Original Article http://dx.doi.org/10.4143/crt.2015.092 Open Access Clinicopathological Features and Type of Surgery for Lynch Syndrome:
More informationFamily history and molecular features of children, adolescents, and young adults with colorectal carcinoma
1146 COLON CANCER Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma C Durno, M Aronson, B Bapat, Z Cohen, S Gallinger... See end of article for
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationFour Novel MSH2 and MLH1 Frameshift Mutations and Occurrence of a Breast Cancer Phenocopy in Hereditary Nonpolyposis Colorectal Cancer
HUMAN MUTATION Mutation in Brief #420 (2001) Online MUTATION IN BRIEF Four Novel MSH2 and MLH1 Frameshift Mutations and Occurrence of a Breast Cancer Phenocopy in Hereditary Nonpolyposis Colorectal Cancer
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationTilburg University. Document version: Publisher's PDF, also known as Version of record. DOI: /s Publication date: 2016
Tilburg University Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer Vasen, Hans F A; Velthuizen, Mary E; Kleibeuker, Jan H; Menko, Fred H; Nagengast, Fokke
More informationHEREDITARY NONPOLYPOSIS
ORIGINAL CONTRIBUTION Genetic Testing in Families With Hereditary Nonpolyposis Colon Cancer Caryn Lerman, PhD Chanita Hughes, PhD Bruce J. Trock, PhD Ronald E. Myers, PhD, DSW David Main, MA, MS Aba Bonney,
More informationMicrosatellite instability in colorectal-cancer patients with suspected genetic predisposition.
Chapter 3 Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola
More informationM. M. Blokhuis G. E. Pietersen P. A. Goldberg U. Algar L. Van der Merwe N. Mbatani A. A. Vorster R. S. Ramesar
Familial Cancer (2010) 9:357 363 DOI 10.1007/s10689-010-9334-9 Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hmlh1 c.c1528t mutation carriers and their mutation-negative
More informationMetachronous colorectal carcinoma with massive submucosal invasion detected by annual surveillance in a Lynch syndrome patient: a case report
Utsumi et al. World Journal of Surgical Oncology (2017) 15:140 DOI 10.1186/s12957-017-1207-3 CASE REPORT Open Access Metachronous colorectal carcinoma with massive submucosal invasion detected by annual
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationScreening Behavior of Individuals at High Risk for Colorectal Cancer
GASTROENTEROLOGY 2005;128:280 287 Screening Behavior of Individuals at High Risk for Colorectal Cancer EVELINE M. A. BLEIKER,* FRED H. MENKO, BABS G. TAAL, IRMA KLUIJT, LIDWINA D. V. WEVER,* MIRANDA A.
More informationHow common are mutations in the MSH2 gene? 1. Mutations that cause Lynch syndrome are rare found in approximately 1 in 370 individuals.
The gene is a tumor suppressor gene. Tumor suppressor genes slow down cell division, repair DNA mistakes, or tell cells when to die. When they don't work properly, cells can grow out of control, which
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationHereditary Colorectal Cancer: The Importance of Recognition as a Preventive Measure
768 International Journal of Collaborative Research on Internal Medicine & Public Health Hereditary Colorectal Cancer: The Importance of Recognition as a Preventive Measure Marcus Valadão, José Antonio
More informationHereditary nonpolyposis colorectal cancer and familial colorectal cancer. in Central part of Iran, Isfahan
Received: 30.1.2011 Accepted: 6.1.2012 Original Article Hereditary nonpolyposis colorectal cancer and familial colorectal cancer in Central part of Iran, Isfahan Amin Nemati 1, Zahra Kazemi Rahmatabadi
More informationHyperplastic polyps in hereditary nonpolyposis colorectal cancer
4 Hyperplastic polyps in hereditary nonpolyposis colorectal cancer F E M Rijcken 1, T van der Sluis 2, H Hollema 2, J H Kleibeuker 1 Department of Gastroenterology 1 and Pathology 2, University Medical
More informationNationwide Study of Clinical and Molecular Features of Hereditary Non-polyposis Colorectal Cancer (HNPCC) in Latvia
Nationwide Study of Clinical and Molecular Features of Hereditary Non-polyposis Colorectal Cancer (HNPCC) in Latvia ARVIDS IRMEJS 1, VIKTORS BOROSENKO 1, INGA MELBARDE-GORKUSA 1, ANDRIS GARDOVSKIS 1, MARIANNA
More informationRazvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationGI Screening/Surveillance in Lynch Syndrome
GI Screening/Surveillance in Lynch Syndrome M Appleyard Royal Brisbane and Women s Hospital Brisbane, Australia GI Disease and Lynch Syndrome What are risks of GI disease in Lynch? Who do we screen for
More informationPost-colonoscopy colorectal cancers in Lynch syndrome
Post-colonoscopy colorectal cancers in Lynch syndrome Francesc Balaguer, MD PhD High Risk Colorectal Cancer Clinic Head of the Gastroenterology Department Hospital Clínic de Barcelona fprunes@clinic.cat
More informationEARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationUptake of genetic testing by the children of Lynch syndrome variant carriers across three generations
https://helda.helsinki.fi Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations Seppala, Toni T. 2017-11 Seppala, T T, Pylvanainen, K & Mecklin, J-P 2017,
More informationProactive Patient Paves the Way for Genetic Testing of Eight Family Members
CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationWhat All of Us Should Know About Cancer and Genetics
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationH ereditary non-polyposis colorectal cancer (HNPCC)
208 LETTER TO JMG Cancer risk in 348 French MSH2 or MLH1 gene carriers Y Parc, C Boisson, G Thomas, S Olschwang... H ereditary non-polyposis colorectal cancer (HNPCC) syndrome is a dominantly inherited
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Syngal, MD, MPH, FACG, 1,2,3 Randall E. Brand, MD, FACG, 4 James M. Church, MD, FACG, 5,6,7
More informationMSI test to distinguish between HNPCC and other predisposing syndromes of value in tailored surveillance 1
Disease Markers 20 (2004) 259 267 259 IOS Press MSI test to distinguish between HNPCC and other predisposing syndromes of value in tailored surveillance 1 Annelie Liljegren a,c, Louise Olsson b and Annika
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationHereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics
From clinic to genetics Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Autosomal dominant Question 2) Incidence of
More informationCLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING
CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace
More informationGenetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes
Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes Policy Number: 2.04.08 Last Review: 1/2014 Origination: 1/2004 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationA636P testing in Ashkenazi Jews
Familial Cancer 3: 223 227, 2004. Ó 2004 Kluwer Academic Publishers. Printed in the Netherlands. A636P testing in Ashkenazi Jews Jose G. Guillem 1, Harvey G. Moore 1, Crystal Palmer 2, Emily Glogowski
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationDiagnostics guidance Published: 22 February 2017 nice.org.uk/guidance/dg27
Molecular testing strategies for Lynch syndrome in people with colorectal cancer Diagnostics guidance Published: 22 February 2017 nice.org.uk/guidance/dg27 NICE 2018. All rights reserved. Subject to Notice
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationFAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry
FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationACG Clinical Guideline: Colorectal Cancer Screening
ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,
More informationColorectal Cancer in 2006: New Developments
James J. Stark, MD Colorectal Cancer in 2006: New Developments Melissa Bennett, MS, CGC Myriad Genetic Laboratories Thomas Duntemann,, MD Ray Ramirez, Jr., MD Hereditary Colon Cancer and Genetic Testing
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationLYNCH SYNDROME (ALSO CALLED
ORIGINAL CONTRIBUTION Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome Judith Balmaña, MD David H. Stockwell, MD, MPH Ewout W. Steyerberg, PhD Elena M. Stoffel, MD, MPH Amie M. Deffenbaugh, BS Julia
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationPathology reports, related operative reports and consult letters must be provided with a request for assessment.
Page 1 of 6 Polyposis Syndromes Inherited risk for colorectal cancer is associated with a number of polyposis syndromes (genes), some of which are well-defined and others are less common. Identification
More informationProtocols 9-12 MMR mutation carrier guidelines Frequently asked questions
Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions Last updated: 10/02/2015 Q: Where have the general population cancer risks been taken from? The risk figures for the general population
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationLYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!
LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic
More informationA Patient s Guide to risk assessment. Hereditary Colorectal Cancer
A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? Overview of Syndromes This workbook is designed to help you decide if hereditary cancer
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationGuidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
s on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer Francis M. Giardiello, MD, 1 John I. Allen, 2 Jennifer E. Axilbund,
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and
More information